Repare Therapeutics (NASDAQ:RPTX - Get Free Report) had its target price cut by investment analysts at Stifel Nicolaus from $9.00 to $4.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Stifel Nicolaus' price target indicates a potential upside of 125.99% from the company's previous close.
Separately, HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Repare Therapeutics in a report on Friday, November 8th.
Check Out Our Latest Stock Analysis on Repare Therapeutics
Repare Therapeutics Stock Down 55.4 %
Shares of RPTX stock traded down $2.20 during trading hours on Friday, hitting $1.77. 4,667,907 shares of the company's stock traded hands, compared to its average volume of 191,428. The stock's fifty day simple moving average is $3.34 and its two-hundred day simple moving average is $3.36. Repare Therapeutics has a 12-month low of $1.66 and a 12-month high of $8.49. The stock has a market cap of $75.24 million, a price-to-earnings ratio of -0.88 and a beta of 0.71.
Institutional Investors Weigh In On Repare Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC lifted its holdings in Repare Therapeutics by 212.1% in the second quarter. Acadian Asset Management LLC now owns 417,929 shares of the company's stock valued at $1,373,000 after acquiring an additional 284,036 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Repare Therapeutics by 30.7% in the 2nd quarter. Renaissance Technologies LLC now owns 458,700 shares of the company's stock worth $1,514,000 after purchasing an additional 107,700 shares during the period. XTX Topco Ltd purchased a new position in shares of Repare Therapeutics in the second quarter worth approximately $110,000. Bank of Montreal Can grew its position in Repare Therapeutics by 5.4% during the second quarter. Bank of Montreal Can now owns 110,935 shares of the company's stock valued at $366,000 after buying an additional 5,673 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Repare Therapeutics during the second quarter valued at approximately $273,000. Hedge funds and other institutional investors own 85.09% of the company's stock.
About Repare Therapeutics
(
Get Free Report)
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
See Also
Before you consider Repare Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repare Therapeutics wasn't on the list.
While Repare Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
